Skip to main content

Publications

Publications

Preclinical Targeted α- and β--Radionuclide Therapy in HER2-Positive Brain Metastasis Using Camelid Single-Domain Antibodies.
Puttemans J, Dekempeneer Y, Eersels JL, Hanssens H, Debie P, Keyaerts M, Windhorst AD, van der Aa F, Lecocq Q, Breckpot K, Morgenstern A, Bruchertseifer F, Lahoutte T, Devoogdt N, D'Huyvetter M.
Cancers (Basel).
2020 Apr 21;12(4):1017. doi: 10.3390/cancers12041017.

Theranostics in immune-oncology using nanobody derivatives. Lecocq Q, De Vlaeminck Y, hanssens H, D’Huyvetter M, Raes G, Goyvaerts C, Keyaerts M, Devoogdt N, Breckpot K. Theranostics 2019; 9(25):7772-7791. Doi:10.7150/thno.34941.

 

Noninvasive Imaging of the Immune Checkpoint LAG-3 Using Nanobodies, from Development to Pre-Clinical Use. Lecocq Q, Zeven K, De Vlaeminck Y, Martens S, Massa S, Goyvaerts C, Raes G, Keyaerts M, Breckpot K, Devoogdt N. Biomolecules. 2019 Sep 29;9(10). pii: E548. doi: 10.3390/biom9100548. PubMed PMID: 31569553.

 

Single Domain Antibody-Mediated Blockade of Programmed Death-Ligand 1 on Dendritic Cells Enhances CD8 T-cell Activation and Cytokine Production. Broos K, Lecocq Q, Keersmaecker B, Raes G, Corthals J, Lion E, Thielemans K, Devoogdt N, Keyaerts M, Breckpot K. . Vaccines (Basel). 2019 Aug 7;7(3). pii: E85. doi: 10.3390/vaccines7030085. PubMed PMID: 31394834; PubMed Central PMCID: PMC6789804.

 

Evaluating a Single Domain Antibody Targeting Human PD-L1 as a Nuclear Imaging and Therapeutic Agent. Broos K, Lecocq Q, Xavier C, Bridoux J, Nguyen TT, Corthals J, Schoonooghe S, Lion E, Raes G, Keyaerts M, Devoogdt N, Breckpot K. Cancers (Basel). 2019 Jun 21;11(6). pii: E872. doi: 10.3390/cancers11060872. PubMed PMID: 31234464; PubMed Central PMCID: PMC6628009.

 

Perforin and Granzyme B Expressed by Murine Myeloid-Derived Suppressor Cells: A Study on Their Role in Outgrowth of Cancer Cells. Dufait I, Pardo J, Escors D, De Vlaeminck Y, Jiang H, Keyaerts M, De Ridder M, Breckpot K. Cancers (Basel). 2019 Jun 11;11(6). pii: E808. doi: 10.3390/cancers11060808. PubMed PMID: 31212684; PubMed Central PMCID: PMC6627828.

 

Single-domain antibody fusion proteins can target and shuttle functional proteins into macrophage mannose receptor expressing macrophages. De Vlaeminck Y, Lecocq Q, Giron P, Heirman C, Geeraerts X, Bolli E, Movahedi K, Massa S, Schoonooghe S, Thielemans K, Goyvaerts C, Van Ginderachter JA, Breckpot K. J Control Release. 2019 Feb 21;299:107-120. doi: 10.1016/j.jconrel.2019.02.023.

 

 Broadening the Message: A Nanovaccine Co-loaded with Messenger RNA and α-GalCer Induces Antitumor Immunity through Conventional and Natural Killer T Cells. Verbeke R, Lentacker I, Breckpot K, Janssens J, Van Calenbergh S, De Smedt SC, Dewitte H. ACS Nano. 2019 Feb 26;13(2):1655-1669. doi: 10.1021/acsnano.8b07660. Epub 2019 Feb 15. 

 

Epigenetic treatment of multiple myeloma mediates tumor intrinsic and extrinsic immunomodulatory effects. De Beck L, Melhaoui S, De Veirman K, Menu E, De Bruyne E, Vanderkerken K, Breckpot K, Maes K. Oncoimmunology. 2018 Jul 23;7(10):e1484981. doi: 10.1080/2162402X.2018.1484981. eCollection 2018.

 

Dendritic Cell Targeting mRNA Lipopolyplexes Combine Strong Antitumor T-Cell Immunity with Improved Inflammatory Safety. Van der Jeught K, De Koker S, Bialkowski L, Heirman C, Tjok Joe P, Perche F, Maenhout S, Bevers S, Broos K, Deswarte K, Malard V, Hammad H, Baril P, Benvegnu T, Jaffrès PA, Kooijmans SAA, Schiffelers R, Lienenklaus S, Midoux P, Pichon C, Breckpot K, Thielemans K. ACS Nano. 2018 Oct 23;12(10):9815-9829. doi: 10.1021/acsnano.8b00966. Epub 2018 Oct 1.

 

The Journey of in vivo Virus Engineered Dendritic Cells From Bench to Bedside: A Bumpy Road. Goyvaerts C, Breckpot K. Front Immunol. 2018 Sep 11;9:2052. doi: 10.3389/fimmu.2018.02052. eCollection 2018. Review.

 

Turn Back the TIMe: Targeting Tumor Infiltrating Myeloid Cells to Revert Cancer Progression. Awad RM, De Vlaeminck Y, Maebe J, Goyvaerts C, Breckpot K. Front Immunol. 2018 Aug 31;9:1977. doi: 10.3389/fimmu.2018.01977. eCollection 2018. Review.

SHOW MORE

PHD theses

1.    Karine Breckpot, 07/2004, ‘Induction of a MAGE-A3 specific cellular immune response by lentivirally transduced dendritic cells’.

2.    Aude Bonehill, 05/2005, ‘Induction of a CD4+ T cell response against MAGE-A3 by mRNA electroporated dendritic cells: introducing T cell help in cancer immunotherapy’.

3.    Melissa Dullaers, 09/2005, ‘HIV-1 derived Lentiviral Vectors as Vehicles for Cancer Vaccination’.

4.    Annelies Michiels, 12/2006, ‘Induction of a MART-1/Melan-A Specific Cellular Immune Response by mRNA Electroporated Dendritic Cells’.

5.    Sandra Tuyaerts, 06/2007, ‘Development of a Dendritic Cell Vaccine for Cancer Immunotherapy’.

6.    Sonia Van Meirvenne, 05/2008, ‘Optimization of a Dendritic Cell Based Cancer Vaccine Evaluated in Mice’’.

7.    Brenda De Keersmaecker, 06/2011, ‘Optimization and immune monitoring of a dendritic cell based HIV vaccine’.

8.    Ann Van Nuffel, 06/2012, ‘Immune monitoring of mRNA loaded DC-therapy – Evaluation of a promising new cancer treatment’.

9.    Sabine Allard, 09/2012, ‘Feasibility, safety and immunogenicity of a dendritic cell-based immunotherapeutic approach in HIV-1-infected patients’.

10. Perpetua U. Emeagi, 12/2012, ‘Lentiviral vectors a versatile tool to evaluate strategies to fight cancer’.

11. Joeri Pen, 03/2014, ‘Targeting immunosuppressive mechanisms that hamper dendritic cell vaccination’.

12. Daphné Benteyn, 03/2014, ‘Autologous dendritic cells and mRNA in cancer immunotherapy’.

13. Sandra Van Lint, 09/2014, ‘Development of a local treatment modality for the systemic cure of cancer using mRNA as a medicinal product’.

14.      Therese Liechtenstein, 05/2015, ‘The role of PD-L1 as a master regulator of antigen-specific immune responses’.

15. Heleen Dewitte, 02/2015, ‘Design and evaluation of immuotheranostic imaging for cancer vaccination’, copromotor.

16. Cleo Goyvaerts, 05/2015, ‘DC-TaLe: Dendritic Cell Targeted Lentiviral vectors’, promotor

17. Sarah Maenhout, 09/2015, ‘Enhancing therapeutic vaccination in melanoma by alleviating STAT3-mediated immune suppression’.

18. Stephanie Dy Four, 01/2016, ‘The bidirectional link between tumor angiogenesis and immunity’.

19. Kevin Van der Jeught, 10/2016, ‘ASPIRE: Adjuvant-driven induction of cancer SPecific Immune REsponses’.

20. Zhuo Ren, 12/2016, ‘The interrelationship between Nucleophomin and STATs under oncogenic settings’.

21. Sofie Wilgenhof, 06/2017, ‘Autologous mRNA electroporated dendritic cell-based immunotherapy for melanoma patients’.

22. Lukasz Bialkowski, 01/2018, ‘Combination therapy for a durable tumor rejection’

23. Ines Dufait, 12/2018, ‘Evaluation of the role of myeloid-derived suppressor cells and GM-CSF in cancer’.

24. Katrijn Broos, 10/2019, 'Evaluation of single domain antibodies specific for PD-L1 as cancer nuclear imaging and therapy agents' 

SHOW MORE